Breaking down next generation CAR-T cell therapy: 2025 A year in review
- Clinical aid
This downloadable clinical aid distils the most significant CAR T therapy developments reported in 2025 for high risk LBCL and relapsed/refractory DLBCL. It brings together key insights from the year’s conference coverage, presenting emerging data, clinical advances, and evolving treatment considerations in a visual format that is free to download and use directly in your clinic.
Enjoyed this content? You might like...
Next-generation CAR-T cell therapy platforms for high-risk LBCL and R/R DLBCL: A round-up of 2025 breakthroughs
Leading experts Marco Davila, Gloria Iacoboni, Sairah Ahmed and Anna Sureda discuss and interpret the year’s most significant breakthroughs in next generation CAR-T cell therapy for high risk LBCL and R/R DLBCL, drawing on landmark data from EHA 2025 and ASH 2025.
